Swissmedic publishes Information concerning an official Warning from Brazil regarding Falsified Medicinal Product
Recommendation
22 October 2026
Good Distribution Practice of Active Substances for Human and Veterinary Medicinal Products
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Swissmedic has been informed by the Brazilian Health Regulatory Agency ANVISA that Brazil has suspended all imports of medicinal products from three Turkish wholesalers. The reason for this is the export of falsified units from Turkey to Brazil. One of the batches was also obtained from Turkey and sold to Brazil by a Swiss wholesaler.
In this regard, an information for Swiss companies was published. The Swissmedic points out that Swiss companies are also not permitted to supply medications obtained from the Turkish wholesalers to Brazil.
The names of the three wholesalers and further information can be found on the website of Swissmedic.
Related GMP News
30.09.2026European GDP Association Developments May through August 2026
30.09.2026Warehouse Temperature Excursions: What Does the FDA Expect?
30.09.2026Version 4.0 of the Swissmedic Document on Notifications of Changes Published
30.09.2026USA: Court Stops Warehouse Activities Following Persistent Insanitary Warehouse Conditions
30.09.2026GDP Non-Compliance Report: CAPA Measures must not only be Promised but also Implemented
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September